PHASE-II STUDY OF CIS-DICHLORODIAMMINEPLATINUM(II) IN ADVANCED BREAST-CANCER

Google Scholar
  • 1 January 1978
    • journal article
    • research article
    • Vol. 62  (3) , 405-408
Abstract
Patients (26) with metastatic breast cancer received cis-dichlorodiammineplatinum(II) either as a single dose of 100 mg/m2 i.v. every 3-4 wk or as a continuous 5 day infusion of 20 mg/m2 per day at 4 wk intervals. Fourteen patients were treated with the single-dose schedule and 12 patients were treated with the continuous 5 day infusion. No significant response was observed with either dose schedule. Aside from a reduction in the frequency and severity of gastrointestinal toxicity with the continuous 5 day infusion, no real difference was seen with regard to renal and hematologic toxicity with either dose schedule.